Morphological and ultrasound characteristics of endometrium in patients with breast cancer and the risk of secondary tumors


Cite item

Full Text

Abstract

The analysis of features of endometrial hyperplasia in patients with breast cancer (BC) receiving adjuvant tamoxifen therapy in the period from 2011 to 2014 inclusive. 196 patients with breast cancer with ultrasound criteria of endometrial hyperplasia were examined. A postoperative histopathologic examination revealed that the lesions were endometrial hyperplasias and with 4,1% malignant findings. Hyperplasia, polyps and endometrial cancer were diagnosed in patients receiving tamoxifen, which allowed a comparison clinicoanamnestic, ultrasound, morphological and genetic characteristics of the endometrium to recover a high risk of developing a second cancer, as well as offer a pathogenic variant of its prevention. The article can be interesting as for obstetrician-gynecologist, watching women after breast cancer treatment, and oncologists, choosing a drug for adjuvant therapy.

About the authors

Aleksey V. Gerasimov

Novosibirsk Regional Clinical Oncological Dispensary

Email: kedrova.anna@gmall.com

doctor

Russian Federation, Novosibirsk st. Plakhotny 2

Sergey E. Krasilnikov

Novosibirsk Regional Clinical Oncological Dispensary

Email: kedrova.anna@gmall.com

head Department of Oncogynecology

Russian Federation, Novosibirsk st. Plakhotny 2

Anna G. Kedrova

Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies FMBA of Russia

Email: kedrova.anna@gmall.com

Doctor of Medical Sciences, Professor, Head. oncology department

Russian Federation, Walnut Boulevard. house 28, Moscow

Tatyana A. Maksimenko

KGBUZ "Altai Regional Oncological Dispensary"

Email: kedrova.anna@gmall.com

head Department of Gynecology

Russian Federation, Zmeinogorsky tract, 110, Barnaul

Nataliya S. Afonina

Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies FMBA of Russia

Email: dr.Afonlna@mall.ru

head of the CHI department

Russian Federation, Walnut Boulevard. house 28, Moscow

Olga E. Nechaeva

Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies FMBA of Russia

Email: kedrova.anna@gmall.com

ultrasound doctor

Russian Federation, Walnut Boulevard. house 28, Moscow

Valentine V. Kosyi

Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies FMBA of Russia

Author for correspondence.
Email: kedrova.anna@gmall.com

Oncologist, Oncology Department

Russian Federation, Walnut Boulevard, house 28, Moscow

References

  1. Kangaspeska S, Hultsch S, Edgren H, et.al. Reanalysis of RNA-Sequencing Data Reveals Several Additional Fusion Genes with Multiple Isoforms. PLoS ONE 7(10): e48745. doi: 10.1371/journal.pone.0048745
  2. Davies C, Pan H, Godwin J, et al; Adjuvant Tamoxifen. Longer Against Shorter (ATLAS) Collaborative Group: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-816.
  3. Bernstein, L., Deapen, D., Cerhan, J.R., Schwartz, S. M., Liff, J., McGann-Maloney, E., et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654-62.
  4. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J. et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000; 356: 881-887.
  5. Goldstein, S.R. The effect of SERMs on the endometrium. Ann. N. Y. Acad. Sci 2001; 949:237-242
  6. Wickerham D.L., Fisher B., Wolmark N., Bryant J., Costantino J., Bernstein L., et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20: 2758-60.
  7. Kim Mi-Jin, Kim Tae-Hee, Lee Hae-Hyeog, et al. G-protein Coupled Estrogen Receptor (GPER/ GPR30) and Women’s Health. J. Menopausal Med. 2015 Aug; 21(2): 79-81.
  8. Du G.Q., Zhou L., Chen X.Y., Wan X.P., and He, Y.Y. The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells. Biochem. Biophys Res Commun 2002;420: 343-49.
  9. Garuti G, Cellani F, Centinaio G, Sita G, Nalli G and Luerti M: Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer. Gynecol Oncol. 2006;101:269-273.
  10. Berlière M, Charles A, Galant C and Donnez J: Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol. 1998, 91:4044.
  11. Clarke R, Cook KL, Hu R, et al: Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res. 2012; 72:1321-1331. Endometrial cancer. Practice Bulletin No. 149. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;125:1006-26.
  12. Haas E, Bhattacharya I, Brailoiu E, et.al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res. 2009 Feb 13;104(3):288-291.
  13. Бочкарева Н.В. Особенности метаболизма и рецепции эстрогенов при гиперпластических процессах и раке эндометрия. Автореферат дисс... докт.мед.наук. Томск, 2007.
  14. Robert J. Kurman, Maria Luisa Carcangiu, C. Simon Herrington, Robert H. Young, (Eds.): WHO Classification of Tumours of Female Reproductive Organs. Tumours of the uterine corpus. IARC: Lyon 2014, p. 121-154.
  15. Plante B, Lessey В., Taylor R., et.al. G ProteinCoupled Estrogen Receptor (GPER) Expression in Normal and Abnormal Endometrium. J. Reproduction Science, 2012 Jul; 19(7): pp. 684-93.
  16. Knapp P, Chabowski A, Blachnio-Zabielska A, Walentowicz-Sadlecka M, Grabiec M, Knapp PA. Expression of estrogen receptors (alpha, beta), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus. Adv Med Sci 2013; 58:96-103.
  17. Prossnitz ER, Barton M. Estrogen biology: new insights into GPER function and clinical opportunities.
  18. Mol Cell Endocrinol 2014; 389: 71-83.
  19. Dedes J.K., Daniel Wetterskog, Alan Ashworth, Stan B. Kaye Emerging therapeutic targets in endometrial cancer Nature Reviews Clinical Oncology 2011;8:261-271.
  20. Smith HO, Leslie KK, Singh M, et.al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol. 2007 Apr; 196(4): 386. e1-9; discussion 386.e9-11.
  21. Prossnitz ER, Barton M. Estrogen biology: new insights into GPER function and clinical opportunities. Mol Cell Endocrinol 2014; 389: 71-83.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1.

Download (185KB)
Indexing metadata
3. Fig. 2. Ultrasound picture of changes in the uterine epithelium during long-term / and taking tamoxifen

Download (224KB)
Indexing metadata
4. Fig. 3

Download (205KB)
Indexing metadata
5. Fig. 4.

Download (243KB)
Indexing metadata
6. Fig. 5.

Download (80KB)
Indexing metadata

Copyright (c) 2015 Gerasimov A.V., Krasilnikov S.E., Kedrova A.G., Maksimenko T.A., Afonina N.S., Nechaeva O.E., Kosyi V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies